Zai Lab and AlphaMa Biotech Entered Into an Agreement to Cooperate in New Drug Discovery - TC Read more about Zai Lab and AlphaMa Biotech Entered Into an Agreement to Cooperate in New Drug Discovery - TC
Zai Lab Announces Financial Results for Second-half and Full-year 2020 - TC Read more about Zai Lab Announces Financial Results for Second-half and Full-year 2020 - TC
Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021 - TC Read more about Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021 - TC
Zai Lab Announces Upcoming Presentations in February Investor Conferences - TC Read more about Zai Lab Announces Upcoming Presentations in February Investor Conferences - TC
Turning Point and Zai Lab Broaden Collaboration - TC Read more about Turning Point and Zai Lab Broaden Collaboration - TC
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China - TC Read more about argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China - TC
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference - TC Read more about Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference - TC
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List - TC Read more about Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List - TC
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China - TC Read more about Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China - TC
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer - TC Read more about Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer - TC